164 related articles for article (PubMed ID: 1937568)
1. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.
Benson JL; Niederkorn JY
Immunology; 1991 Sep; 74(1):153-9. PubMed ID: 1937568
[TBL] [Abstract][Full Text] [Related]
2. Efferent blockade of delayed-type hypersensitivity responses in the anterior chamber of the eye.
Niederkorn JY; Benson JL; Mayhew E
Reg Immunol; 1990-1991; 3(6):349-54. PubMed ID: 2132760
[TBL] [Abstract][Full Text] [Related]
3. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.
Knisely TL; Niederkorn JY
Cancer Immunol Immunother; 1990; 30(6):323-30. PubMed ID: 2302723
[TBL] [Abstract][Full Text] [Related]
4. The immunopathology of intraocular tumour rejection.
Niederkorn JY
Eye (Lond); 1991; 5 ( Pt 2)():186-92. PubMed ID: 2070879
[TBL] [Abstract][Full Text] [Related]
5. T-cell-mediated immune responses in alloepithelial rejection after murine keratoepithelioplasty.
Miyazaki D; Inoue Y; Yao YF; Okada AA; Shimomura Y; Hayashi K; Tano Y; Ohashi Y
Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2590-7. PubMed ID: 10509654
[TBL] [Abstract][Full Text] [Related]
6. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
[TBL] [Abstract][Full Text] [Related]
7. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
Niederkorn JY; Streilein JW
J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
[TBL] [Abstract][Full Text] [Related]
8. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes.
Ma D; Alizadeh H; Comerford SA; Gething MJ; Sambrook JF; Anand R; Niederkorn JY
Curr Eye Res; 1994 May; 13(5):361-9. PubMed ID: 7914482
[TBL] [Abstract][Full Text] [Related]
9. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice.
Yao YF; Inoue Y; Miyazaki D; Hara Y; Shimomura Y; Tano Y; Ohashi Y
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):292-300. PubMed ID: 9040461
[TBL] [Abstract][Full Text] [Related]
10. T cell subsets in the immune rejection of murine heterotopic corneal allografts.
Matoba AY; Peeler JS; Niederkorn JY
Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1244-54. PubMed ID: 2942516
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
Streilein JW; Niederkorn JY
J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
[TBL] [Abstract][Full Text] [Related]
12. T-cell mediated responses in a murine model of orthotopic corneal transplantation.
Joo CK; Pepose JS; Stuart PM
Invest Ophthalmol Vis Sci; 1995 Jul; 36(8):1530-40. PubMed ID: 7601633
[TBL] [Abstract][Full Text] [Related]
13. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
14. Immune privilege in the anterior chamber of the eye: alloantigens and tumour-specific antigens presented into the anterior chamber simultaneously induce suppression and activation of delayed hypersensitivity to the respective antigens.
Benson JL; Niederkorn JY
Immunology; 1992 Oct; 77(2):189-95. PubMed ID: 1427974
[TBL] [Abstract][Full Text] [Related]
15. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens.
Peeler JS; Niederkorn JY
J Immunol; 1986 Jun; 136(12):4362-71. PubMed ID: 3519767
[TBL] [Abstract][Full Text] [Related]
16. Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases.
Li XY; Mayhew E; Niederkorn JY
Curr Eye Res; 1995 Aug; 14(8):719-26. PubMed ID: 8529408
[TBL] [Abstract][Full Text] [Related]
17. Ocular immune privilege and CTL tolerance.
McKenna KC; Kapp JA
Immunol Res; 2004; 29(1-3):103-12. PubMed ID: 15181274
[TBL] [Abstract][Full Text] [Related]
18. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.
Ksander BR; Mammolenti MM; Streilein JW
Transplantation; 1991 Jul; 52(1):128-33. PubMed ID: 1907041
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulation of intraocular tumours.
Niederkorn JY
Eye (Lond); 1997; 11 ( Pt 2)():249-54. PubMed ID: 9349421
[TBL] [Abstract][Full Text] [Related]
20. Characterization of specific T helper cell activity in mice bearing alloantigenic tumors in the anterior chamber of the eye.
Bando Y; Ksander BR; Streilein JW
Eur J Immunol; 1991 Aug; 21(8):1923-31. PubMed ID: 1831132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
